Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer
Prostate-specific membrane antigen (PSMA) is an important cell-surface imaging biomarker
and therapeutic target in prostate cancer. The PSMA-targeted theranostic 177Lu-PSMA-617 …
and therapeutic target in prostate cancer. The PSMA-targeted theranostic 177Lu-PSMA-617 …
Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapies for prostate cancer
Abstract Purpose of Review Prostate-specific membrane antigen (PSMA)-targeted
radionuclide therapy (TRT) is a promising investigational treatment for metastatic castration …
radionuclide therapy (TRT) is a promising investigational treatment for metastatic castration …
Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond
PSMA is a transmembrane protein that is markedly overexpressed in prostate cancer,
making it an excellent target for imaging and treating patients with prostate cancer. Several …
making it an excellent target for imaging and treating patients with prostate cancer. Several …
Outcome of patients with PSMA PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis
The aim of the study was to assess the outcome of patients with metastatic castration-
resistant prostate cancer treated with 177Lu-prostate-specific membrane antigen (PSMA) …
resistant prostate cancer treated with 177Lu-prostate-specific membrane antigen (PSMA) …
Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation …
ST Tagawa, C Thomas, AO Sartor, M Sun… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE Novel therapies are needed to extend survival in metastatic castration-resistant
prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface …
prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface …
Computational Analysis of Treatment Resistant Cancer Cells
A Matov - medRxiv, 2024 - medrxiv.org
Prostate cancer (PC), which is a disease driven by the activity of the androgen receptor (AR),
is the most commonly diagnosed malignancy and despite advances in diagnostic and …
is the most commonly diagnosed malignancy and despite advances in diagnostic and …
PSMA PET tumor–to–salivary gland ratio to predict response to [177Lu] PSMA radioligand therapy: an international multicenter retrospective study
Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy can improve the
outcome of patients with advanced metastatic castration-resistant prostate cancer, but …
outcome of patients with advanced metastatic castration-resistant prostate cancer, but …
Quantitative Microscopy in Medicine
A Matov, S Modiri - medRxiv, 2024 - medrxiv.org
Introduction Methods for personalizing medical treatment are the focal point of contemporary
biomedical research. In cancer care, we can analyze the effects of therapies at the level of …
biomedical research. In cancer care, we can analyze the effects of therapies at the level of …
177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art
Background Prostate specific membrane antigen (PSMA) ligand labeled with Lutetium-177
(177Lu) is a promising therapeutic option for metastatic castration-resistant prostate cancer …
(177Lu) is a promising therapeutic option for metastatic castration-resistant prostate cancer …
[PDF][PDF] PSMA expression assessed by PET imaging is a required biomarker for selecting patients for any PSMA-targeted therapy
J Calais, J Czernin - Journal of Nuclear Medicine, 2021 - Soc Nuclear Med
Approximately 20% of breast cancers express human epidermal growth factor receptor 2
(Erb-B2 receptor tyrosine kinase 2 [ERBB2], formerly HER2), and 70% express estrogen or …
(Erb-B2 receptor tyrosine kinase 2 [ERBB2], formerly HER2), and 70% express estrogen or …